

## **Main Analysis of the Primary Endpoint**

### **Primary Objective**

The primary objective of the study was to determine the need for, optimal timing of, and immune response following administration of an mRNA booster vaccination against SARS-CoV-2 in adults ( $\geq 18$  years) previously vaccinated with mRNA SARS-CoV-2 vaccines. If the efficacy criterion was met, additional analyses were conducted to determine the optimal timing of a booster dose. This was assessed by modelling the schedule–response relationship using a logistic regression model where the timing of the booster dose was included as the predictor.

### **Primary Endpoint Hypothesis**

The primary hypothesis tested whether, in at least one booster arm, the proportion of responders exceeded 50%. The primary endpoint was analysed using a one-sample, one-sided hypothesis test, with control of the family-wise error rate at 0.05 using the Bonferroni correction. As this analysis assessed the response rate within each booster arm against a predefined threshold (50%), no direct comparison between study arms was performed in the main analysis.

### **Statistical Hypothesis Testing and Estimation**

**Null Hypothesis ( $H_0$ ):** The proportion of responders at each booster timing group  $\leq 50\%$  ( $p \leq 0.50$ )

**Alternative Hypothesis ( $H_1$ ):** The proportion of responders of at least one booster timing group  $> 50\%$  ( $p > 0.50$ )

Booster Timing Group	n/N*	Proportion (95% CI)	P-value (>50%)
Booster BI (Baseline)	29/50	58.0% (44.2 to 70.6%)	0.16
Booster 2m (2 months)	35/47	74.5% (60.5 to 84.7%)	<b>&lt;0.001*</b>
Booster 4m (4 months)	23/48	47.9% (34.5 to 61.7%)	0.56
Booster 6m (6 months)	26/44	59.1% (44.4 to 72.3%)	0.15

*Figure 22: Number (n) and proportion of participants meeting the primary and titre-based secondary endpoints for each treatment arm using complete cases (N\* indicates the number of non-missing observations). Proportions are shown as percentages with Wilson 95% confidence intervals (CIs). P-values are one-sided (whether proportions are larger than 50%) and calculated using a one-sample proportion test (based on a normal approximation). Values below the pre-defined threshold (0.0125) are indicated with an asterisk.*

### **Statistical Methods**

For each booster timing arm, the proportion of responders was estimated with its 95% confidence interval (CI). A one-sample, one-sided test of proportion was used to evaluate whether the observed response rate exceeded the predefined threshold of 50%. To control the family-wise type I error rate at 0.05 across the four booster timing arms, Bonferroni correction was applied.

### **Conditional Analysis of Booster Timing and Presentation of Results**

The 2-month booster group met this criterion (74.5%, 95% CI 60.5–84.7%;  $p < 0.001$ ). As specified in the statistical analysis plan, meeting this efficacy criterion triggered an additional analysis to explore optimal booster timing. This analysis modelled the schedule-response relationship using a logistic regression with the best fitting fractional polynomials of grade 2 for the randomized booster timing group. The results reported therefore correspond to this prespecified schedule-response modelling analysis.